Immunomodulatory effects of polysaccharopeptide in immunosuppressed mice induced by cyclophosphamide

Huang,Rui; Zhang,Jun; Liu,Yong; Hao,Yingying; Yang,Chenchen; Wu,Kangkang; Cao,Shufeng; Wu,Chao

doi:10.3892/mmr.2013.1542

Immunomodulatory effects of polysaccharopeptide in immunosuppressed mice induced by cyclophosphamide

Authors:
- Rui Huang
- Jun Zhang
- Yong Liu
- Yingying Hao
- Chenchen Yang
- Kangkang Wu
- Shufeng Cao
- Chao Wu
View Affiliations

Affiliations: Department of Infectious Disease, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210008, P.R. China, Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China, Department of Infectious Disease, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China
Published online on: June 25, 2013 https://doi.org/10.3892/mmr.2013.1542
Pages: 669-675

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polysaccharopeptide (PSP) is well known for its immunoregulatory effects. In the present study, the effect of PSP on white blood cell (WBC) count, T lymphocyte subsets, B lymphocytes, Th1/Th2 balance and negative immune regulators was investigated using an immunosuppressed mouse model. The results demonstrated that the WBC count and the absolute number of CD3+CD4+ T cells, CD3+CD8+ T cells and CD3‑CD19+ B cells in the peripheral blood were increased in PSP‑treated groups as compared with the cyclophosphamide (Cy) group. In addition, PSP reduced interleukin (IL)‑4 and GATA binding protein 3 (GATA‑3) mRNA relative expression levels and elevated the ratios of IL‑2/IL‑4 and the transcription factors, T‑box‑containing protein/GATA‑3. The relative mRNA expression levels of the forkhead/winged‑helix transcription factor box protein 3 (Foxp3), programmed death‑1 (PD‑1) and IL‑10 were also downregulated by PSP. These observations indicate that the immunoregulatory effects of PSP are associated with restoration of WBC number, improving the absolute number of T lymphocyte subsets and B lymphocytes, inducing the Th1/Th2 response and downregulating the negative immune regulators, Foxp3, PD‑1 and IL‑10.

View Figures

View References

1	Hyde HA and Adams KF: Airborne allergens at Cardiff 1942–59. Acta Allergol Suppl (Copenh). 7:159–169. 1960.PubMed/NCBI
2	Chu KK, Ho SS and Chow AH: Coriolus versicolor: a medicinal mushroom with promising immunotherapeutic values. J Clin Pharmacol. 42:976–984. 2002. View Article : Google Scholar
3	Yang MM, Chen Z and Kwok JS: The anti-tumor effect of a small polypeptide from Coriolus versicolor (SPCV). Am J Chin Med. 20:221–232. 1992. View Article : Google Scholar : PubMed/NCBI
4	Cui J and Chisti Y: Polysaccharopeptides of Coriolus versicolor: physiological activity, uses, and production. Biotechnol Adv. 21:109–122. 2003.
5	Ng TB: A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol. 30:1–4. 1998. View Article : Google Scholar : PubMed/NCBI
6	Kidd PM: The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 5:4–27. 2000.PubMed/NCBI
7	Collins RA and Ng TB: Polysaccharopeptide from Coriolus versicolor has potential for use against human immunodeficiency virus type 1 infection. Life Sci. 60:PL383–PL387. 1997.PubMed/NCBI
8	Yang X, Sit WH, Chan DK and Wan JM: The cell death process of the anticancer agent polysaccharide-peptide (PSP) in human promyelocytic leukemic HL-60 cells. Oncol Rep. 13:1201–1210. 2005.PubMed/NCBI
9	Li J, Bao Y, Lam W, et al: Immunoregulatory and anti-tumor effects of polysaccharopeptide and Astragalus polysaccharides on tumor-bearing mice. Immunopharmacol Immunotoxicol. 30:771–782. 2008. View Article : Google Scholar : PubMed/NCBI
10	Li W, Liu M, Lai S, Xu C, Lu F, Xiao X and Bao Y: Immunomodulatory effects of polysaccharopeptide (PSP) in human PBMC through regulation of TRAF6/TLR immunosignal-transduction pathways. Immunopharmacol Immunotoxicol. 32:576–584. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lee CL, Jiang PP, Sit WH and Wan JM: Proteome of human T lymphocytes with treatment of cyclosporine and polysaccharopeptide: analysis of significant proteins that manipulate T cells proliferation and immunosuppression. Int Immunopharmacol. 7:1311–1324. 2007. View Article : Google Scholar : PubMed/NCBI
12	Shin H and Wherry EJ: CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol. 19:408–415. 2007. View Article : Google Scholar : PubMed/NCBI
13	Wherry EJ: T cell exhaustion. Nat Immunol. 12:492–499. 2011. View Article : Google Scholar
14	Huyan XH, Lin YP, Gao T, Chen RY and Fan YM: Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. Int Immunopharmacol. 11:1293–1297. 2011. View Article : Google Scholar : PubMed/NCBI
15	Tornatore KM, Reed K and Venuto R: 24-hour immunologic assessment of CD4⁺ and CD8⁺ lymphocytes in renal transplant recipients receiving chronic methylprednisolone. Clin Nephrol. 44:290–298. 1995.PubMed/NCBI
16	Huang GC, Wu LS, Chen LG, Yang LL and Wang CC: Immuno-enhancement effects of Huang Qi Liu Yi Tang in a murine model of cyclophosphamide-induced leucopenia. J Ethnopharmacol. 109:229–235. 2007. View Article : Google Scholar : PubMed/NCBI
17	de Jonge ME, Huitema AD, Rodenhuis S and Beijnen JH: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 44:1135–1164. 2005.
18	Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F and Proietti E: Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood. 95:2024–2030. 2000.PubMed/NCBI
19	Zhu XL, Chen AF and Lin ZB: Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol. 111:219–226. 2007. View Article : Google Scholar
20	Bafna AR and Mishra SH: Immunostimulatory effect of methanol extract of Curculigo orchioides on immunosuppressed mice. J Ethnopharmacol. 104:1–4. 2006. View Article : Google Scholar : PubMed/NCBI
21	Bafna AR and Mishra SH: Protective effect of bioactive fraction of Sphaeranthus indicus Linn. against cyclophosphamide induced suppression of humoral immunity in mice. J Ethnopharmacol. 104:426–429. 2006.PubMed/NCBI
22	Gergely P: Drug-induced lymphopenia: focus on CD4⁺ and CD8⁺ cells. Drug Saf. 21:91–100. 1999. View Article : Google Scholar : PubMed/NCBI
23	Bao YX, Wong CK, Leung SF, et al: Clinical studies of immunomodulatory activities of Yunzhi-Danshen in patients with nasopharyngeal carcinoma. J Altern Complement Med. 12:771–776. 2006. View Article : Google Scholar : PubMed/NCBI
24	Wong CK, Bao YX, Wong EL, Leung PC, Fung KP and Lam CW: Immunomodulatory activities of Yunzhi and Danshen in post-treatment breast cancer patients. Am J Chin Med. 33:381–395. 2005. View Article : Google Scholar : PubMed/NCBI
25	Abbas AK, Murphy KM and Sher A: Functional diversity of helper T lymphocytes. Nature. 383:787–793. 1996. View Article : Google Scholar : PubMed/NCBI
26	Warren HS, Vogel FR and Chedid LA: Current status of immunological adjuvants. Annu Rev Immunol. 4:369–388. 1986. View Article : Google Scholar : PubMed/NCBI
27	Blachère NE, Morris HK, Braun D, Saklani H, Di Santo JP, Darnell RB and Albert ML: IL-2 is required for the activation of memory CD8⁺ T cells via antigen cross-presentation. J Immunol. 176:7288–7300. 2006.
28	Lafreniere JF, Mills P, Bouchentouf M and Tremblay JP: Interleukin-4 improves the migration of human myogenic precursor cells in vitro and in vivo. Exp Cell Res. 312:1127–1141. 2006. View Article : Google Scholar : PubMed/NCBI
29	Bowen H, Kelly A, Lee T and Lavender P: Control of cytokine gene transcription in Th1 and Th2 cells. Clin Exp Allergy. 38:1422–1431. 2008. View Article : Google Scholar : PubMed/NCBI
30	Ho CY, Lau CB, Kim CF, et al: Differential effect of Coriolus versicolor (Yunzhi) extract on cytokine production by murine lymphocytes in vitro. Int Immunopharmacol. 4:1549–1557. 2004.
31	Lee CL, Sit WH, Jiang PP, So IW and Wan JM: Polysaccharopeptide mimics ciclosporin-mediated Th1/Th2 cytokine balance for suppression of activated human T cell proliferation by MAPKp38 and STAT5 pathways. J Pharm Pharmacol. 60:1491–1499. 2008. View Article : Google Scholar : PubMed/NCBI
32	Baecher-Allan C, Brown JA, Freeman GJ and Hafler DA: CD4⁺CD25high regulatory cells in human peripheral blood. J Immunol. 167:1245–1253. 2001.PubMed/NCBI
33	Fowler S and Powrie F: Control of immune pathology by IL-10-secreting regulatory T cells. Springer Semin Immunopathol. 21:287–294. 1999. View Article : Google Scholar : PubMed/NCBI
34	Powrie F, Carlino J, Leach MW, Mauze S and Coffman RL: A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4⁺ T cells. J Exp Med. 183:2669–2674. 1996. View Article : Google Scholar : PubMed/NCBI
35	Sakaguchi S, Ono M, Setoguchi R, et al: Foxp3⁺ CD25⁺ CD4⁺ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 212:8–27. 2006.
36	Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
37	Wan YY and Flavell RA: Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature. 445:766–770. 2007. View Article : Google Scholar : PubMed/NCBI
38	Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA and Rudensky AY: Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 445:771–775. 2007. View Article : Google Scholar : PubMed/NCBI
39	Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895. 1992.PubMed/NCBI
40	Okazaki T, Iwai Y and Honjo T: New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol. 14:779–782. 2002. View Article : Google Scholar : PubMed/NCBI
41	Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 4:336–347. 2004. View Article : Google Scholar : PubMed/NCBI
42	Greenwald RJ, Freeman GJ and Sharpe AH: The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005. View Article : Google Scholar : PubMed/NCBI
43	Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ and Sharpe AH: Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 33:2706–2716. 2003. View Article : Google Scholar : PubMed/NCBI
44	Rodig N, Ryan T, Allen JA, et al: Endothelial expression of PD-L1 and PD-L2 down-regulates CD8⁺ T cell activation and cytolysis. Eur J Immunol. 33:3117–3126. 2003. View Article : Google Scholar : PubMed/NCBI
45	Seo SK, Seo HM, Jeong HY, et al: Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunol Lett. 102:222–228. 2006. View Article : Google Scholar : PubMed/NCBI
46	Ding H, Wu X and Gao W: PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin Immunol. 115:184–191. 2005. View Article : Google Scholar : PubMed/NCBI
47	Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, Minato N and Honjo T: Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 84:57–62. 2002. View Article : Google Scholar : PubMed/NCBI
48	Parry RV, Chemnitz JM, Frauwirth KA, et al: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 25:9543–9553. 2005. View Article : Google Scholar : PubMed/NCBI
49	Chemnitz JM, Parry RV, Nichols KE, June CH and Riley JL: SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 173:945–954. 2004. View Article : Google Scholar : PubMed/NCBI
50	Kim HK, Guan H, Zu G, et al: High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals. J Leukoc Biol. 79:686–695. 2006. View Article : Google Scholar : PubMed/NCBI
51	Barber DL, Wherry EJ, Masopust D, et al: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 439:682–687. 2006. View Article : Google Scholar : PubMed/NCBI
52	Fiorentino DF, Bond MW and Mosmann TR: Two types of mouse T helper cell. IV Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 170:2081–2095. 1989. View Article : Google Scholar : PubMed/NCBI
53	Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA and Mosmann TR: Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 248:1230–1234. 1990. View Article : Google Scholar
54	Mosser DM and Zhang X: Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 226:205–218. 2008. View Article : Google Scholar : PubMed/NCBI
55	O’Garra A and Vieira P: T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 7:425–428. 2007.PubMed/NCBI